FullText URL fulltext.pdf
Author Yamamoto, Shumpei| Onishi, Hideki| Takaki, Akinobu| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Sakata, Masahiro| Yasunaka, Tetsuya| Shiraha, Hidenori| Okada, Hiroyuki|
Keywords Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Low-dose cisplatin plus 5-fluorouracil alpha-Fetoprotein Des-gamma-carboxy prothrombin
Published Date 2020-04-21
Publication Title Gastrointestinal Tumors
Volume volume7
Issue issue3
Publisher Karger
Start Page 83
End Page 92
ISSN 2296-3774
NCID AA12665877
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Author(s)
File Version publisher
DOI 10.1159/000506941
Web of Science KeyUT 000551254300003
Related Url isVersionOf https://doi.org/10.1159/000506941
JaLCDOI 10.18926/AMO/56935
FullText URL 73_4_333.pdf
Author Kuwaki, Kenji| Nouso, Kazuhiro| Miyashita, Manabi| Makino, Yasuhiro| Hagihara, Hiroaki| Moriya, Akio| Adachi, Takuya| Wada, Nozomu| Yasunaka, Yuki| Yasunaka, Tetsuya| Takeuchi, Yasuto| Onishi, Hideki| Nakamura, Shinichiro| Ikeda, Fusao| Shiraha, Hidenori| Takaki, Akinobu| Okada, Hiroyuki|
Abstract Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE), a standard treatment of hepatocellular carcinoma (HCC), with the expectation of preventing postembolization syndrome. Here we investigated the precise effects of steroids on TACE. We prospectively enrolled 144 HCC patients from 10 hospitals who underwent TACE. Three hospitals used steroids (steroid group, n=77) and the rest did not routinely use steroids (control group, n=67). The occurrence of adverse events and the algetic degree at 1-5 days post-treatment were compared between the groups. Fever (grades 0-2) after TACE was significantly less in the steroid group (56/21/0) compared to the control group (35/29/3, p=0.005, Cochran-Armitage test for trend). The suppressive effect of steroids against fever was prominent in females (p=0.001). Vomiting (G0/G1/ G2-) was also less frequent in the steroid group (70/5/2) versus the control group (53/10/3), but not significantly (p=0.106). The algetic degree and the grade of hematological adverse events, including hyperglycemia, did not differ between the groups. We conclude that the administration of steroids was useful for the prevention of adverse events after TACE in patients with HCC.
Keywords antipyretic hepatocellular carcinoma therapeutic chemoembolization steroid
Amo Type Original Article
Published Date 2019-08
Publication Title Acta Medica Okayama
Volume volume73
Issue issue4
Publisher Okayama University Medical School
Start Page 333
End Page 339
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31439956
JaLCDOI 10.18926/AMO/56457
FullText URL 73_1_43.pdf
Author Ikeda, Ailee| Takaki, Akinobu| Yasunaka, Tetsuya| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Onishi, Hideki| Ikeda, Fusao| Shiraha, Hidenori| Yoshida, Kazuhiro| Kuise, Takashi| Nobuoka, Daisuke| Yoshida, Ryuichi| Umeda, Yuzo| Yagi, Takahito| Fujiwara, Toshiyoshi| Okada, Hiroyuki|
Abstract Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.
Keywords acute liver failure hepatitis B hepatitis B vaccine liver cirrhosis liver transplantation
Amo Type Original Article
Published Date 2019-02
Publication Title Acta Medica Okayama
Volume volume73
Issue issue1
Publisher Okayama University Medical School
Start Page 41
End Page 50
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30820053
JaLCDOI 10.18926/AMO/56178
FullText URL 72_4_401.pdf
Author Wada, Nozomu| Ikeda, Fusao| Mori, Chizuru| Takaguchi, Koichi| Fujioka, Shin-ichi| Kobashi, Haruhiko| Morimoto, Yoichi| Kariyama, Kazuya| Sakaguchi, Kosaku| Hashimoto, Noriaki| Moriya, Akio| Kawaguchi, Mitsuhiko| Miyatake, Hirokazu| Hagihara, Hiroaki| Kubota, Junichi| Takayama, Hiroki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Takaki, Akinobu| Iwasaki, Yoshiaki| Okada, Hiroyuki|
Abstract Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the efficacy of this therapy by focusing on the factors associated with sustained virological responses (SVR) including resistance-associated variants (RAVs) and mixed infection of different HCV genotypes. We enrolled 951 HCV serogroup 1-positive patients who received this combination therapy at our hospital or affiliated hospitals. The presence of RAVs in non-structural (NS) regions 3 and 5A was analyzed by direct sequencing. HCV genotypes were determined by PCR with genotype-specific primers targeting HCV core and NS5B regions. SVR was achieved in 91.1% of patients. Female sex, age > 70 years, and RAVs were significantly associated with non-SVR (p<0.01 for all). Propensity score-matching results among the patients without RAVs regarding sex, age, and fibrosis revealed that mixed HCV infection determined by HCV NS5B genotyping showed significantly lower SVR rates than 1B-mono infection (p=0.02). Female sex and RAVs were significant factors associated with treatment failure of this combination therapy for patients with HCV serogroup 1 infection. Mixed HCV infection other than 1B-mono infection would be useful for predicting treatment failure.
Keywords mixed genotype daclatasvir asunaprevir HCV serogrouping 1 infection
Amo Type Original Article
Published Date 2018-08
Publication Title Acta Medica Okayama
Volume volume72
Issue issue4
Publisher Okayama University Medical School
Start Page 401
End Page 406
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30140089
JaLCDOI 10.18926/AMO/56074
FullText URL 72_3_283.pdf
Author Namba, Shihoko| Ikeda, Fusao| Takaguchi, Koichi| Shimomura, Yasuyuki| Yasunaka, Tetsuya| Okada, Hiroyuki|
Abstract We investigated whether a small amount of blood collected by fingertip blood sampling would be adequate in a mass examination for hepatitis virus infection in Japan. A cross-sectional survey was conducted at health fairs in Kasaoka City and Shodoshima Island, where participants took the hepatitis screening test. A total of 114 consecutive individuals who took the hepatitis screening test were enrolled. Twenty microliters of plasma was successfully obtained from all participants. Among the participants, two had positive results for HBs antigen and two were positive for anti-HCV; all four were > 60 years old and rarely visited the hospital. Thirty-three and 38 patients chronically infected with HBV and HCV, respectively, were examined for confirmatory assays at participating hospitals. All subjects with undetectable serum levels of HBs antigen and anti-HCV had undetectable levels of both markers in fingertip blood, and the levels in serum and fingertip blood were significantly correlated (p<0.01). The lower detection limit of HBs antigen was defined as 0.005 IU/ml, and the cut-off value of anti-HCV was 1.0 by using 10-μl fingertip blood samples. The fingertip blood sampling described herein may be adequate in mass examinations for hepatitis virus testing in Japan.
Keywords fingertip hepatitis test HBV HCV Japan
Amo Type Original Article
Published Date 2018-06
Publication Title Acta Medica Okayama
Volume volume72
Issue issue3
Publisher Okayama University Medical School
Start Page 283
End Page 287
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29926006
JaLCDOI 10.18926/AMO/55662
FullText URL 72_1_47.pdf
Author Ako, Soichiro| Nakamura, Shinichiro| Nouso, Kazuhiro| Dohi, Chihiro| Wada, Nozomu| Morimoto, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Kuwaki, Kenji| Onishi, Hideki| Ikeda, Fusao| Shiraha, Hidenori| Takaki, Akinobu| Okada, Hiroyuki|
Abstract Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2%. A multivariate regression analysis revealed that a large tumor size (p< 0.01) and a long interval between the therapies (p= 0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10% can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size
Keywords hepatocellular carcinoma transcatheter arterial chemoembolization radiofrequency ablation interval size reduction
Amo Type Original Article
Published Date 2018-02
Publication Title Acta Medica Okayama
Volume volume72
Issue issue1
Publisher Okayama University Medical School
Start Page 47
End Page 52
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29463938
JaLCDOI 10.18926/AMO/55435
FullText URL 71_5_381.pdf
Author Yoshida, Kazuhiro| Umeda, Yuzo| Takaki, Akinobu| Nagasaka, Takeshi| Yoshida, Ryuichi| Nobuoka, Daisuke| Kuise, Takashi| Takagi, Kosei| Yasunaka, Tetsuya| Okada, Hiroyuki| Yagi, Takahito| Fujiwara, Toshiyoshi|
Abstract Determining the indications for and timing of liver transplantation (LT) for acute liver failure (ALF) is essential. The King’s College Hospital (KCH) guidelines and Japanese guidelines are used to predict the need for LT and the outcomes in ALF. These guidelines’ accuracy when applied to ALF in different regional and etiological backgrounds may differ. Here we compared the accuracy of new (2010) Japanese guidelines that use a simple scoring system with the 1996 Japanese guidelines and the KCH criteria for living donor liver transplantation (LDLT). We retrospectively analyzed 24 adult ALF patients (18 acute type, 6 sub-acute type) who underwent LDLT in 1998-2009 at our institution. We assessed the accuracies of the 3 guidelines’ criteria for ALF. The overall 1-year survival rate was 87.5%. The new and previous Japanese guidelines were superior to the KCH criteria for accurately predicting LT for acute-type ALF (72% vs. 17%). The new Japanese guidelines could identify 13 acute-type ALF patients for LT, based on the timing of encephalopathy onset. Using the previous Japanese guidelines, although the same 13 acute-type ALF patients (72%) had indications for LT, only 4 patients were indicated at the 1st step, and it took an additional 5 days to decide the indication at the 2nd step in the other 9 cases. Our findings showed that the new Japanese guidelines can predict the indications for LT and provide a reliable alternative to the previous Japanese and KCH guidelines.
Keywords living donor liver transplantation acute liver failure fulminant hepatic failure
Amo Type Original Article
Published Date 2017-10
Publication Title Acta Medica Okayama
Volume volume71
Issue issue5
Publisher Okayama University Medical School
Start Page 381
End Page 390
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29042695
JaLCDOI 10.18926/AMO/53996
FullText URL 70_1_1.pdf
Author Yasunaka, Tetsuya| Ikeda, Fusao| Wada, Nozomu| Morimoto, Yuki| Fujioka, Shin-ichi| Toshimori, Junichi| Kobashi, Haruhiko| Kariyama, Kazuya| Morimoto, Yoichi| Takayama, Hiroki| Seno, Tomonori| Takaguchi, Koichi| Moriya, Akio| Miyatake, Hirokazu| Okamoto, Ryoichi| Yabushita, Kazuhisa| Takaki, Akinobu| Yamamoto, Kazuhide|
Abstract Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged &#8805; 35 years, HBV DNA &#8805; 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged &#8805; 35 years with HBV DNA &#8805; 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged&#8805;35 years with HBV DNA &#8805;4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.
Keywords entecavir hepatitis B virus lamivudine hepatocellular carcinoma
Amo Type Original Article
Published Date 2016-02
Publication Title Acta Medica Okayama
Volume volume70
Issue issue1
Publisher Okayama University Medical School
Start Page 1
End Page 12
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26899604
Web of Science KeyUT 000371288700001
Author Nakatsuka, Atsuko| Matsuyama, Makoto| Yamaguchi, Satoshi| Katayama, Akihiro| Eguchi, Jun| Murakami, Kazutoshi| Teshigawara, Sanae| Ogawa, Daisuke| Wada, Nozomu| Yasunaka, Tetsuya| Ikeda, Fusao| Takaki, Akinobu| Watanabe, Eijiro| Wada, Jun|
Published Date 2016-02-17
Publication Title Scientific Reports
Volume volume6
Content Type Journal Article
Author Katayama, Akihiro| Nakatsuka, Atsuko| Eguchi, Jun| Murakami, Kazutoshi| Teshigawara, Sanae| Kanzaki, Motoko| Nunoue, Tomokazu| Hida, Kazuyuki| Wada, Nozomu| Yasunaka, Tetsuya| Ikeda, Fusao| Takaki, Akinobu| Yamamoto, Kazuhide| Kiyonari, Hiroshi| Makino, Hirofumi| Wada, Jun|
Published Date 2015
Publication Title Scientific reports
Volume volume5
Content Type Journal Article
JaLCDOI 10.18926/AMO/53558
FullText URL 69_4_219.pdf
Author Toshimori, Junichi| Nouso, Kazuhiro| Nakamura, Shinichiro| Wada, Nozomu| Morimoto, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Kuwaki, Kenji| Ohnishi, Hideki| Ikeda, Fusao| Shiraha, Hidenori| Takaki, Akinobu| Yamamoto, Kazuhide|
Abstract We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). HCC patients (n=397) consecutively treated with RFA (256 males, 141 females, median age 69 years) were enrolled. In these patients, 1,455 nodules (median size 17mm) were ablated. Predisposing factors for overall recurrence and local recurrence in the context of tumor location and complications were examined. Local recurrence was observed for 113 of the 1,455 nodules. The 1-, 3- and 5-year local recurrence rates were 2.2オ, 7.4オ and 9.5オ, respectively. A multivariate Cox proportional hazard analysis revealed that large tumor size (>2cm), tumor location (adjacent to the major portal branch or hepatic vein), and small ablated margin (<3mm) were independent predisposing factors for local recurrence after RFA (HR=1.70-2.81). Tumor location (adjacent to the major portal branch, hepatic vein, or diaphragm) was also revealed as a risk factor for liver damage due to RFA. HCC adjacent to the major portal vein or hepatic vein was associated with a higher risk for local recurrence and for complications;therefore, special precautions are necessary when applying RFA to HCC near vessels even when the tumors are located at an easy-to-puncture site.
Keywords hepatocellular carcinoma radiofrequency ablation ablated margin tumor location
Amo Type Original Article
Published Date 2015-08
Publication Title Acta Medica Okayama
Volume volume69
Issue issue4
Publisher Okayama University Medical School
Start Page 219
End Page 226
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26289913
Web of Science KeyUT 000365519100005
JaLCDOI 10.18926/AMO/53520
FullText URL 69_3_137.pdf
Author Seki, Hiroyuki| Ikeda, Fusao| Nanba, Shintaro| Moritou, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Nakamura, Minoru| Yamamoto, Kazuhide|
Abstract A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptomatic primary biliary cirrhosis (aPBC). We performed a systematic cohort analysis of 101 patients diagnosed as having aPBC and the rapid progression to liver failure in some, by focusing on cholestasis. Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patientsʼ hepatocytes. Intralobular expressions of K-7 were found in 9 of the 101 patients. The grades of K-7 expression were significantly associated with the levels of alanine aminotransferase, alkaline phosphatase, and total bilirubin at the time of diagnosis, but not with bile duct loss or cholestasis. Stepwise logistic regression analysis revealed that high grades of K-7 expression correlated positively with high levels of total bilirubin. During the follow-up period, 8 patients developed jaundice, and the mean period until the development of jaundice was 5.2 years. The proportional hazards models for the risk of developing jaundice identified a high grade of aberrant K-7 expression in hepatocytes as the only significant risk factor. Aberrant K-7 expression in hepatocytes can be used as an additional marker to predict rapid progression to liver failure in patients with aPBC at the time of diagnosis.
Keywords primary biliary cirrhosis keratin 7 hepatic failure
Amo Type Original Article
Published Date 2015-06
Publication Title Acta Medica Okayama
Volume volume69
Issue issue3
Publisher Okayama University Medical School
Start Page 137
End Page 144
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26101189
Web of Science KeyUT 000356903000002
Author Shoji, Bon| Ikeda, Fusao| Fujioka, Shin-ichi| Kobashi, Haruhiko| Yasunaka, Tetsuya| Miyake, Yasuhiro| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
Published Date 2010-11
Publication Title Journal of Gastroenterology
Volume volume45
Issue issue11
Content Type Journal Article
Author Ishikawa, Hisashi| Takaki, Akinobu| Tsuzaki, Ryuichiro| Yasunaka, Tetsuya| Koike, Kazuko| Shimomura, Yasuyuki| Seki, Hiroyuki| Matsushita, Hiroshi| Miyake, Yasuhiro| Ikeda, Fusao| Shiraha, Hidenori| Nouso, Kazuhiro| Yamamoto, Kazuhide|
Published Date 2014-07-01
Publication Title PLoS ONE
Volume volume9
Issue issue7
Content Type Journal Article
Author Takeuchi, Yasuto| Ikeda, Fusao| Moritou, Yuki| Hagihara, Hiroaki| Yasunaka, Tetsuya| Kuwaki, Kenji| Miyake, Yasuhiro| Ohnishi, Hideki| Nakamura, Shinichiro| Shiraha, Hidenori| Takaki, Akinobu| Iwasaki, Yoshiaki| Nouso, Kazuhiro| Yamamoto, Kazuhide|
Published Date 2013-03
Publication Title Journal of Gastroenterology
Volume volume48
Issue issue3
Content Type Journal Article
Author Matsushita, Hiroshi| Ikeda, Fusao| Iwasaki, Yoshiaki| Seki, Hiroyuki| Nanba, Shintaro| Takeuchi, Yasuto| Moritou, Yuki| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Yamamoto, Kazuhide|
Published Date 2014-02
Publication Title Journal of Gastroenterology and Hepatology
Volume volume29
Issue issue2
Content Type Journal Article
Author Ohnishi, Atsuyuki| Miyake, Yasuhiro| Matsushita, Hiroshi| Matsumoto, Kazuyuki| Takaki, Akinobu| Yasunaka, Tetsuya| Koike, Kazuko| Ikeda, Fusao| Shiraha, Hidenori| Nouso, Kazuhiro| Yamamoto, Kazuhide|
Published Date 2012
Publication Title Digestion
Volume volume86
Issue issue2
Content Type Journal Article
JaLCDOI 10.18926/AMO/52790
FullText URL 68_4_243.pdf
Author Wada, Nozomu| Yasunaka, Tetsuya| Ikeda, Fusao| Nishina, Sohji| Korenaga, Masaaki| Hino, Keisuke| Fujioka, Shin-ichi| Osawa, Toshiya| Itoshima, Tatsuya| Kawanaka, Miwa| Yamada, Gotaro| Kariyama, Kazuya| Takayama, Hiroki| Kubota, Junichi| Morimoto, Yoichi| Mizushima, Takaaki| Yamashita, Haruhiko| Tanioka, Hiroaki| Negoro, Yuji| Toshimori, Junichi| Kobashi, Haruhiko| Hirano, Atsushi| Itano, Yasuo| Takaki, Akinobu| Yamamoto, Kazuhide|
Abstract Hepatitis B virus (HBV) is one of the major viruses causing acute hepatitis. Recently, the incidence of acute hepatitis with genotype A has been increasing in Japan. The aim of this study was to investigate acute hepatitis B (AHB) in Okayama prefecture, with special attention to HBV genotype A. AHB patients who visited one of 12 general hospitals in Okayama prefecture between 2006 and 2010 were retrospectively analyzed. Over the course of the study period, 128 patients were diagnosed with AHB. Sexual transmission was supposed in the majority of patients (78 patients, 61%), including 59 (76%) having sex with heterosexual partners. The genotypes of HBV were assessed in 90 patients (70%), of whom 27 patients were infected with genotype A, 5 with genotype B, and 58 with genotype C. The prevalence of genotype A was significantly higher among male patients (28.7%), aged 20-29 (35.6%, p<0.01), among men who had sex with men (100%, p<0.005), and among patients having sex with unspecified partners (44.8%, p<0.005). Genotype A was not a significant factor associated with delayed HBsAg disappearance. Caution should be exercised with regard to sexually transmissible diseases in order to slow the pandemic spread of AHB due to genotype A.
Keywords acute hepatitis hepatitis B virus
Amo Type Original Article
Published Date 2014-08
Publication Title Acta Medica Okayama
Volume volume68
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 247
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 25145410
Web of Science KeyUT 000340687500006
JaLCDOI 10.18926/AMO/52139
FullText URL 68_1_17.pdf
Author Moritou, Yuki| Ikeda, Fusao| Iwasaki, Yoshiaki| Baba, Nobuyuki| Takaguchi, Kouichi| Senoh, Tomonori| Nagano, Takuya| Takeuchi, Yasuto| Yasunaka, Tetsuya| Ohnishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Yamamoto, Kazuhide|
Abstract The impact of hepatic steatosis on interferon therapy for patients with chronic hepatitis C (CHC) has been associated with single-nucleotide polymorphisms (SNP) of IL28B, patatin-like phospholipase domain-containing protein 3 (PNPLA3), and low-density lipoprotein (LDL) receptor. Whether this holds true for Japanese patients, however, remains unresolved. The present study prospectively enrolled 226 Japanese patients with CHC, and investigated the impact of hepatic steatosis and its related SNPs, including rs8099917 of IL28B, rs738409 of PNPLA3, and rs14158 of LDL receptor, on outcomes of peg-interferon and ribavirin therapy. In multivariate logistic regression analysis, significant factors affecting the severity of hepatic steatosis were high body mass index and the minor alleles of IL28B SNP (p=0.020 and 0.039, respectively). The risk alleles of PNPLA3 SNP also showed weak association (p=0.059). Severe steatosis and the minor alleles of IL28B SNP were significantly associated with null or partial virological response in patients with HCV genotype 1, as were female gender, and low LDL cholesterol (p=0.049, and <0.001, respectively). The SNP genotype of PNPLA3 and LDL receptor did not have a significant impact on therapeutic outcomes. With respect to the SNP sites examined, the SNP of PNPLA3 has a weak association with severe hepatic steatosis, but not with the outcome of interferon therapy.
Keywords hepatic steatosis genetic polymorphism interferon HCV
Amo Type Original Article
Published Date 2014-02
Publication Title Acta Medica Okayama
Volume volume68
Issue issue1
Publisher Okayama University Medical School
Start Page 17
End Page 22
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 24553484
Web of Science KeyUT 000331592800003
Author Kinugasa, Hideaki| Nouso, Kazuhiro| Takeuchi, Yasuto| Yasunaka, Tetsuya| Onishi, Hideki| Nakamura, Shin-ichiro| Shiraha, Hidenori| Kuwaki, Kenji| Hagihara, Hiroaki| Ikeda, Fusao| Miyake, Yasuhiro| Takaki, Akinobu| Yamamoto, Kazuhide|
Published Date 2012-04
Publication Title Journal of Gastroenterology
Volume volume47
Issue issue4
Content Type Journal Article